Perjeta

This page shows the latest Perjeta news and features for those working in and with pharma, biotech and healthcare.

Hemlibra off to a flyer as Roche raises 2019 forecasts

It’s looking likely to overtake Roche’s older breast cancer Perjeta (pertuzumab), which rose 41% to CHF 868m in the quarter and has been another big growth driver for the

Latest news

AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

trastuzumab) and Perjeta (pertuzumab), and have disease progression after Kadcyla treatment. ... That is however well behind the $7bn and $2.8bn added to the company’s coffers by Herceptin and Perjeta.
Biosimilar Herceptin helps Roche gain new Perjeta recommendation

now recommendation of a new use for Perjeta will make the NHS an early adopter. ... Richard Erwin, Roche UK's general manager (pictured) said: “Roche has worked closely with NICE and other health stakeholders to help make Perjeta available as quickly
Roche submits Kadcyla for FDA Real-Time review

Herceptin and follow-up Perjeta are already approved for neoadjuvant use in this indication, but it doesn’t always clear away all tumour tissue, which could dramatically increase the risk of
Ocrevus helps Roche shrug off biosimilars in 2018

All told, new products accounted for 90% of Roche’s sales growth in 2018, with another big boost provided by the company’s breast cancer drug Perjeta (pertuzumab), up 27% to
Roche preps new Kadcyla filings after phase 3 trial win

Neoadjuvant therapy is given with the intention of achieving a cure for patients with early-stage cancer, and Herceptin and follow-up HER2 drug Perjeta (pertuzumab) have been approved for this ... With Herceptin and follow-up Perjeta (pertuzumab) already

More from news
Approximately 17 fully matching, plus 44 partially matching documents found.

Latest Intelligence

Back to the future

In 2013, Roche's biologics sales totalled $29.2bn. These were led by established oncology brands such as Avastin and MabThera/Rituxan, along with emerging breast cancer therapies such as Perjeta

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Account Director, Medical Education: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

PR Associate Director – Consumer Health & Beauty: Salary TBC

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Senior Medical Writer: Competitive salary and benefits

Director – Healthcare PR: Salary TBC

Editor – Medical Education Agency – Bucks: Salary TBC

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Senior Medical Writer: Salary TBC

Editorial/ Medical Director – Med Ed & Comms – Home-based...: Salary TBC

Home-based Principal Medical Writer – Medical Comms: Salary TBC

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Subscribe to our email news alerts

PMHub

Add my company

Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...